Molecular determinants of atrial fibrillation susceptibility and progression.

房颤易感性和进展的分子决定因素。

• 批准号: 333137
• 负责人: Nattel Stanley
• 金额: $ 322.21万
• 依托单位: Montreal Heart Institute
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2015
• 资助国家: 加拿大
• 起止时间: 2015-09-01 至 2022-09-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=333137&lang=en
• 关键词: Atrial Fibrillation; Cardiac Action Potentials; Cardiac Antiarrhythmic Drugs; Cardiac Calcium Handling; Cardiac Electrophysiology; Cardiac Ion Channels; Cardiovascular Pharmacology; Fibrosis; Heart Disease Treatments; New Cardiac Arrhythmia Therapy Target

Atrial fibrillation (AF) is the most common cardiac rhythm disorder. It can cause a host of problems, including reduced physical capacity, chest discomfort, heart fluttering, heart failure and strokes, and increases the chance of dying. Present treatments

心房颤动（AF）是最常见的心律失常。它会导致一系列问题，包括身体能力下降、胸部不适、心悸、心力衰竭和中风，并增加死亡的机会。目前治疗